Company news
Basilea Pharmaceutica AG news in 2025
Basilea Pharmaceutica AG's news releases, calls and decks from 2025, newest first.
Phare Bio and Basilea Announce Landmark Partnership to Develop Next-Generation Broad-Spectrum Antibiotic Using AI
December 11, 2025
Basilea and Phare Bio enter partnership combining anti-infectives industry expertise with unique AI capabilities for the development of a novel antibiotic
December 11, 2025
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 30 million milestone payment to Basilea
November 4, 2025
Basilea awarded BARDA contract for the development of novel oral phase 3-ready antibiotic ceftibuten-ledaborbactam
September 25, 2025
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
September 16, 2025
Basilea on track with strong 2025 half-year results
August 19, 2025
Basilea announces in-licensing of a novel clinical phase 3-ready oral antibiotic
August 14, 2025
Basilea initiates phase 3 study with antifungal fosmanogepix in invasive mold infections
July 29, 2025
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
July 8, 2025
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea
June 5, 2025
Basilea announces commercial availability of antibiotic Zevtera® (ceftobiprole) in the United States
May 20, 2025
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
April 24, 2025
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
April 16, 2025
Basilea reports presentation of new data for fosmanogepix, isavuconazole (Cresemba®) and ceftobiprole (Zevtera®) at ESCMID Global 2025
April 16, 2025
Basilea reports strong 2024 full-year results with significant increase in revenue, profit and operating cash flow
February 18, 2025